NL-OMON37508CompletedPhase 2
Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trial - Hydroxychloroquine and erlotinib in NSCLC
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 136
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •* Histologically confirmed stage IV non-squamous NSCLC patients.
- •* Patients:
- •with an activating EGFR mutation who progressed on erlotinib or gefitinib monotherapy.
- •who failed after at least one line of platinum based doublet chemotherapy and who are EGFR TKI naïve.
- •* At least one measurable disease site, defined as a lesion of * 1 cm in at least one dimension on CT-scan.
- •* WHO performance status 0-2.
- •* No symptomatic brain metastases.
- •* Absolute neutrophil count of at least 1500/*l, platelet count of at least 100000/*l and hemoglobin level at least 6 mmol/l.
- •* Calculated creatinine clearance of at least 60 ml/min.
- •* Adequate hepatic function: Total bilirubin * 1.5 x upper limit of normal (ULN); ALT, AST, and alkaline phosphatase * 2.5 x ULN (in case of liver metastases * 5 x ULN).
- •* Willing and able to comply with the study prescriptions
- •* 18 years or older.
- •* Not pregnant or breast feeding and willing to take adequate contraceptive measures during the study.
- •* Ability to give and having given written informed consent before patient registration.
- •* No recent (< 3 months) severe (NYHA class >1) cardiac disease (congestive heart failure, infarction). No history of cardiac arrythmia (multifocal premature ventricular contractions, uncontrolled atrial fibrillation, bigeminy, trigeminy, ventricular tachycardia) which is symptomatic and requiring treatment (CTC AE 4.0), or asymptomatic sustained ventricular tachycardia. Asymptomatic atrial fibrillation controlled on medication is allowed.
- •* No cardiac conduction disturbances or medication potentially causing them: congenital long QT-syndrome or unexplained sudden death of first degree relative under 40 years of age, QT interval > 480 msec (note: when this is the case on screening ECG, the ECG may be repeated twice. If the average QT-interval of these 3 measurements remains below 480 msec, patient is eligible). Patients on medication potentially prolonging the QT-interval are excluded if the QT-interval is > 460 msec. Medication that might cause QT-prolongation or Torsades de pointes tachycardia is not allowed. Drugs with a risk of prolonging the QT-interval that cannot be discontinued are allowed, however, under close monitoring by the treating physician.
- •* No uncontrolled infectious disease.
- •* No clinically significant gastrointestinal abnormalities.
- •* No other active malignancy.
- •* No major surgery (excluding diagnostic procedures like e.g. mediastinoscopy or VATS biopsy) in the previous 4 weeks.
- •* No treatment with investigational drugs in the 4 weeks prior to or during this study that are thought or known to interact with autophagy or the EGFR axis.
- •* No known G6PD deficiency.
- •* No psoriasis or porphyria.
- •* No known hypersensitivity to 4-aminoquinoline compound.
- •* No retinal or visual field changes from prior 4-aminoquinoline compound use.
- •* No known prior hypersensitivity to erlotinib, HCQ or any of their components.
Exclusion Criteria
- •We refer to the inclusion criteria
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Treatment with hydroxychloroquine and erlotinib in patients with non-small-cell lung cancerPatients with histologically confirmed stage IV non-squamous non-small-cell lung cancer (NSCLC)• with an activating EGFR mutation who progressed on erlotinib or gefitinib monotherapy. OR• who failed after at least one line of platinum based doublet chemotherapy and who are EGFR TKI naïve.EUCTR2011-004903-20-NL136
Completed
Not Applicable
Hydroxychloroquine and erlotinib in NSCLC.histologically confirmed stage IV non-squamous NSCLC patients who are eligible to start with EGFR targeted therapy1.patients who progressed on erlotinib or gefitinib monotherapy after having experienced an initial response.2.patients who failed chemotherapy after at least one line of platinum based doublet chemotherapy and who are EGFR TKI naïveDutch:Histologisch bewezen stadium IV non-squamous NSCLC patienten.• Patienten:• met een activerende EGFR mutatie die progressief zijn onder erlotinib of gefitinib monotherapie.OF• welke progressieve ziekte hebben na eerdereNL-OMON21406VU University Medical Center136
Active, not recruiting
Phase 1
Autophagy inhibition using hydrochloroquine in breast cancer patients: a pilot study - HCQ TRIAEUCTR2010-022842-26-NLniversity Medical Centre Nijmegen20
Recruiting
Phase 2
Autophagy inhibition using hydrochloroquine in breast cancer patients: a pilot study10006291breast cancerNL-OMON34049niversitair Medisch Centrum Sint Radboud20
Completed
Not Applicable
Chloroquine as an anti-autophagic chemosensitizing drug in stage IV small cell lung cancer (SCLC) patients: A phase I trial.10029107small cell lung cancerNL-OMON37990MAASTRO clinic24